Involvement of MMP2/9 in the pathogenesis of uterine adenomyosis and mechanisms of PVA combined recombinant human endostatin
article
OA: closed
CC0
AI-generated summary
This study found that PVA combined with recombinant human endostatin normalized adenomyosis symptoms and significantly increased MMP2/9 levels, suggesting a therapeutic mechanism involving these matrix metalloproteinases.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
Abstract
Objective:The present research aimed to explore the involvement of MMP2/9in the pathogenesis of uterine adenomyosis and mechanisms of PVA combined recombinant human endostatin.Methods:80cases of uterine denomyosis patients were divided into 2groups,recombinant human endostatin(RHD)group and PVA combined RHD group.The degree of dysmenorrhea,menstrual blood volume and uterine size were analyzed in each group.The content of MMP2 and MMP9in each group was also be detected.The aforementioned parameters were also assayed before drug treatment in uterine adenomysis patients.Results:PVA combined RHD normalized the affected dysmenorrhea,menstrual blood volume and uterine size as well as up-regulated MMP2 and MMP9greatly with a statistical difference.Conclusion:PVA combined RHD remedy uterine adenomysis by inhibiting aberrant MMP9 and MMP9.
My notes (saved in your browser only)
Condition tags
Citation neighborhood (no data yet)
We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.
Source provenance
- openalex
- last seen: 2026-06-10T17:14:06.276822+00:00
License: CC0
· commercial use OK